The role of PIM3 in the chemoresistance of PDAC was shown through either genetic or pharmacological inhibition (i.e., SGI-1776), suggesting that PIM3 inhibition could be a potential strategy to sensitize PDAC cells to gemcitabine and improve treatment outcomes in patients with this aggressive cancer [101]. This evidence concerns the gene PIM3 and cancer.